	US 12,222,347 B2
	Ligand discovery and gene delivery via retroviral surface display
Michael Birnbaum, Arlington, MA (US); and Connor Dobson, Somerville, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Aug. 30, 2023, as Appl. No. 18/458,657.
Application 18/458,657 is a continuation of application No. 16/826,665, filed on Mar. 23, 2020, granted, now 12,061,187.
Claims priority of provisional application 62/851,889, filed on May 23, 2019.
Prior Publication US 2024/0230627 A1, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/50 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)

CPC G01N 33/505 (2013.01) [C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 14/5437 (2013.01); C07K 14/70532 (2013.01); C07K 14/70539 (2013.01); C07K 16/2803 (2013.01); C12N 15/86 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/035 (2013.01); C07K 2319/60 (2013.01); C12N 2740/15045 (2013.01)]

15 Claims

1. A lentivirus comprising:

(a) a nucleic acid encoding a gene of interest; and

(b) a viral envelope that comprises at least two different proteins: (i) a vesicular stomatitis virus (VSV-G) envelope protein comprising an amino acid sequence at least 97% identical to SEQ ID NO: 13, wherein the VSV-G envelope protein comprises an amino acid substitution at position 47 (lysine, K) and an amino acid substitution at position 354 (arginine, R) to alanine (A) or glutamine (Q); and

(ii) a non-viral membrane-bound protein comprising a transmembrane domain and an extracellular targeting domain that binds to a T cell or B cell.